Chikungunya vaccine: The Lancet provides a detailed analysis of final Phase 1 results
by Press Release from Outbreak News Today on (#549JR)
Valneva SE, a specialty vaccine company, announced today the publication of full data from the Phase 1 clinical trial of its chikungunya vaccine candidate, VLA1553, in the peer-reviewed medical journal The Lancet Infectious Diseases. The Lancet paper provides a detailed analysis of final Phase 1 results and supports the continued clinical development of VLA1553. Wolfgang Bender, Ph.D., M.D., [...]
The post Chikungunya vaccine: The Lancet provides a detailed analysis of final Phase 1 results appeared first on Outbreak News Today.